대한핵의학회지 (1967년~2009년)
대한핵의학회지 2000;34(4)265~11
분화성 갑상선암의 방사성옥소 치료 ( Radioiodine Therapy For Differentiatd Thyroid Cancer )
()
Author 홍성운(Sung Woon Hong),
Affiliation
Abstract

The thyroid gland is an interesting endocrine organ where a spectrum of tumors with different behavior arise. At one end of spectrum there is differentiated thyroid carcinoma (DTC) with excellent prognosis, whereas at the other end of the spectrum is anaplastic thyroid cancer which has universally poor outcome. Radioiodine (I-131) therapy has been in use for the treatment of thyroid diseases since 1946. It was introduced by Seidlin et al. 1) Although the use of I-131 has been vouge for a long time, its use in therapy for well differentiated thyroid cancer is still controversial 2). This is because, thyroid cancers (TC) are generally slow growing tumors, with low mortality and normal spans of survival. To record recurrence and mortality, long term follow up studies over a period of two to three decades are needed to establish definite conclusions on the acceptable mode of treatment . The incidence of the disease being very low a large number of cases needed to establish a meaningful statistical data is lacking as most published reports deal with small series. Here again in the problem encountered are the differing protocols for treatment with I-131, the indications for treatment which may include or exclude ablation of residual thyroid tissue, cervical nodal and distal metastases. The dosage of I-131 used for ablation of residual thyroid tissue and metastatic disease also vary. The most reliable conclusion regarding I-131 treatment are obtained from studies reported on a large series of patients followed over a period of 2 decades or more from a single institute with a more or less unchanged protocol of management. (Korean J Nucl Med 2000;34:265-75)

Keyword N/ADifferentiated thyroid cancer, I-131 treatment, Ablation
Full text Article 28503265.pdf 28503265.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)